The pharmaceutical company—Allow’s call them Business X, for your hell of it—won’t be manufacturing copyright tablets. This isn’t like a hit of Molly you purchase off a girl sporting white fuzzy boots at an outdoor live performance in the course of summer time. Firm X might be making the active pharmaceutical ingredient, or API: the 99 pe